CiplaPrivate▲ Positive
Regulationrelevance
FDA approval for generic Advair Diskus across all strengths, enabling market entry.
Cipla Limited has received U.S. FDA approval for its generic version of Advair Diskus across all three strengths. The approval covers 100/50 mcg, 250/50 mcg, and 500/50 mcg doses of the fluticasone propionate and salmeterol inhalation powder, a widely prescribed combination therapy for asthma and COPD. Cipla's product is a therapeutically equivalent, lower-cost alternative in a U.S. market estimated at $908 million according to IQVIA. This marks Cipla's first dry powder inhaler approval from its U.S. manufacturing network, representing a significant milestone in expanding complex respiratory capabilities in the United States. The stock closed Tuesday's trading at INR 1,444.60, up 2.50%.
FDA approval for generic Advair Diskus across all strengths, enabling market entry.